The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism
| Autor: | M. G. Siniauskaya, L.A. Anisko, O. G. Davydenko, S. P. Lukashyk, O.V. Krasko, I. A. Karpov, N. G. Danilenko |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
direct-acting antiviral agents Epidemiology business.industry efficacy lcsh:QR1-502 UGT1A1*28 polymorphism 030226 pharmacology & pharmacy ugt1a1\*28 adverse events lcsh:Microbiology lcsh:Infectious and parasitic diseases hcv infection 03 medical and health sciences 0302 clinical medicine Infectious Diseases Immunology Medicine 030211 gastroenterology & hepatology Pharmacology (medical) In patient lcsh:RC109-216 business Direct acting |
| Zdroj: | Клиническая микробиология и антимикробная химиотерапия, Vol 22, Iss 1, Pp 71-80 (2020) |
| ISSN: | 2686-9586 1684-4386 |
| Popis: | Objective. To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism. Materials and Methods. An open-label, non-randomized, observational study to assess efficacy and safety of DAA in patients (n = 143) with chronic hepatitis C (CHC) and liver cirrhosis and UGT1A1*28 polymorphism was performed. A total of 139 patients with chronic HCV infection were included in the efficacy analysis (absence of HCV RNA in blood by PCR) by the rate of sustained virologic response at week 12 (SVR12). Results. The SVR12 rate in patients with CHC and HCV-CP was 92.5% and 87.9%, respectively (p = 0.508), regardless of the presence of UGT1A1*28 polymorphism. The SVR12 rate in patients with chronic HCV infection and (TA)7/(TA)7 was 84.8%, with (TA)6/(TA)7 – 92.2% compared with (TA)6/ (TA)6 – 90,5% (p = 0.518). The rate of SVR12 in patients with CHC and (TA)7/(TA)7 or (TA)6/(TA)7 was 80% and 95%, respectively, with (TA)6/(TA)6 – 95.2%. The rate of SVR12 in patients with liver cirrhosis and (TA)7/(TA)7 or (TA)6/(TA)7 was 92.3% and 87.5%, respectively, with (TA)6/(TA)6 – 85.7%. The rate of SVR12 in patients with 12- and 24-week treatment duration was 88.2% and 96.6%, respectively (p = 0.30). As many as 96.2% of patients with the previous treatment with interferon and ribavirin had SVR12 compared to 88.5% of patients who have not previously taken antiviral drugs (p = 0.486). Grade 1 adverse events (AE) occurred in 24% of patients with chronic HCV infection treated with DAA; two patients developed Grade 4 AE. Conclusions. The treatment with DAA was shown to be effective and safe in patients with chronic HCV infection and UGT1A1*28 polymorphism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|